CTIS2023-507008-30-00招募中1 期
Immunogenicity Profile of Neoadjuvant Keytruda in Combination with Anthracycline versus Carboplatin/PAclitaxel Containing Chemotherapy Regimen for The Treatment of Early-stage, TILs-Positive, Triple-Negative Breast CanceR (KeyPARTNER) - N/A
Champalimaud Clinical Centre0 个研究点目标入组 20 人开始时间: 2023年11月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be willing and able to provide written informed consent for the trial., Male participants: A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 12 months after the last dose of cyclophosphamide or 6 months after last chemotherapy (whichever occurs last) and refrain from donating sperm during this period. Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 12 months after the last dose of cyclophosphamide or 6 months after last chemotherapy (whichever occurs last)., Be a female or male participant who is at least 18 years of age on the day of signing informed consent., Have locally histologically confirmed diagnosis of invasive carcinoma of the breast that is classified as TNBC, as defined by the most recent ASCO/CAP guidelines., Has locally confirmed tumor infiltrating lymphocytes (stromal) (sTILs) equal to or above 10%, as defined by the most recent International Guidelines on TIL Assessment in Breast Cancer., Have previously untreated non-metastatic (M0) TNBC defined as the following combined primary tumor (T) and regional lymph node (N) staging per current AJCC staging criteria for breast cancer staging criteria as assessed by the investigator based on radiological and/or clinical assessment: a. T1c, N1-N2; b. T2, N0-N2; c. T3, N0-N2; d. T4a-d, N0-N2., Provide a core needle biopsy consisting of at least 3 separate tumor cores from the primary tumor at screening to the designated central biobank (or responsible laboratories) and is willing to provide a second biopsy at the end of the first cycle of treatment., Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 10 days of treatment initiation., Have left ventricular ejection fraction (LVEF) of =50% or = institution lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening., Have adequate organ function as defined in Table 2 of this protocol. Specimens must be collected within 28 days prior to the start of study intervention.
排除标准
- •Has a history of invasive malignancy =5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer., Has had an allogenic tissue/solid organ transplant., Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months., Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)., Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 4 weeks of the first dose of treatment in this current trial., Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Administration of killed vaccines is allowed., Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug., Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed., Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease., Has significant cardiovascular disease, such as: a. History of myocardial infarction, acute coronary syndrome or coronary angioplasty/stenting/bypass grafting within the last 6 months; b. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV or history of CHF NYHA class III or IV., Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial and to consent, Has a known history of Human Immunodeficiency Virus (HIV) infection., Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection., Has a known history of active TB (Bacillus Tuberculosis)., Has an active infection requiring systemic therapy., If surgery was performed prior to screening, has persistent adverse events or incomplete wound healing considered clinically relevant by the treating investigator., Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant‘s participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator., Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial., Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 12 months after the last dose of cyclophosphamide or 6 months after last chemotherapy (whichever occurs last).
研究者
相似试验
进行中（未招募）
2 期
A study to investigate if atezolizumab can reduce the size of urothelial cancer before surgery and to determine how the drug worksrothelial cancer (upper tract urothelial carcinoma and rare histological subtypes of bladder cancer)Malignant neoplasms of urinary tractCancerISRCTN22771691Queen Mary University of London58
招募中
1 期
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancerMuscle invasive bladder cancer set to undergo radical cystectomy who cannot receive orrefuse to receive cisplatin-based chemotherapyMedDRA version: 20.0Level: PTClassification code: 10005003Term: Bladder cancer Class: 100000004864CTIS2024-513957-55-00CatalYm GmbH30
进行中（未招募）
1 期
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2020-001028-32-FRCHU DE NIMES99
尚未招募
不适用
Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients with Resectable Gastrointestinal CancersNeoplasmsKCT0004253Asan Medical Center48
尚未招募
3 期
A Partially-Blinded, Randomized, Phase 3 Study to Evaluate the Immunogenicity and Safety of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Healthy Adults and Individuals with HIV Infectiosevere acute respiratory syndrome coronavirus 2 SARS CoV 2PACTR202108616900606Clover Biopharmaceuticals AUS Pty Ltd600